{"id":"e98fe010da78","type":"article","url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","title":"2021 ACC consensus: ASCVD-risicoreductie bij persistente hypertriglyceridemie","title_en":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["dyslipidemie"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2021.06.011","source_url":"https://doi.org/10.1016/j.jacc.2021.06.011","authors":["Salim S Virani","Pamela B Morris","Anandita Agarwala","Christie M Ballantyne","Kim K Birtcher","Penny M Kris-Etherton","Amanda B Ladden-Stirling","Michael Miller","Carl E Orringer","Neil J Stone"],"significance":8,"published":"2021-08-31","source_date":"2021-08-31","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"The 2021 ACC Expert Consensus addressed ASCVD risk reduction in patients with persistent hypertriglyceridemia, providing decision algorithms integrating icosapent ethyl, fibrates, and lifestyle modification based on the REDUCE-IT and STRENGTH evidence.","created":"2026-07-03T10:29:20Z","updated":"2026-07-03T13:28:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC 2021 expert consensus over management van ASCVD-risicoreductie bij patiënten met persistente hypertriglyceridemie.","abstract_original":""}